SCHEMBL4776062

SCHEMBL4776062

CCCC[Sn](CCCC)(CCCC)c1ccc(S(=O)(=O)CCCOC)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
MMP13 P45452 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MMP8 P22894 1/20 0.40
MMP1 P03956 1/20 0.39
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PNMT P11086 1/20 0.39
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
LOX P28300 1/20 0.36
CA2 P00918 3/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
TSHR P16473 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763911 0.85 ALDH1A1 (0.43) ALDH1A1MMP13CYP3A4CYP2C9CYP2C19
SCHEMBL4773643 0.81 LMNA (0.39) ALDH1A1MMP13CYP3A4CYP2C9CYP2C19
SCHEMBL4766681 0.81 ALDH1A1 (0.60) ALDH1A1TSHRSMN1; SMN2KDM4ENPC1
SCHEMBL4765265 0.76 ATM (0.41) ALDH1A1CYP3A4CYP2C9LOXCA2
SCHEMBL4770531 0.76 PTGS2 (0.43) CA2SMN1; SMN2
SCHEMBL4098679 0.75 ALDH1A1 (0.71) ALDH1A1MMP13CYP3A4CYP2C9CYP2C19
SCHEMBL4773979 0.73 CA2 (0.56) CA2CA12CA1TSHRCA7
SCHEMBL1940015 0.73 PLCG1 (0.52) ALDH1A1MMP13CYP3A4CYP2C9CYP2C19
SCHEMBL3847841 0.73 TDP1 (0.35) ALDH1A1CA2CA12CA1TSHR
SCHEMBL14081009 0.73 MAPK1 (0.57) ALDH1A1MMP13CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885MMP13 3820/4885CYP3A4 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.